Biopharmaceutical firm TG Therapeutics has obtained a license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to aid the development of a novel immunotherapy. In return, MaxCyte will receive annual licensing fees and program-related revenue. TG Therapeutics, focused on B-cell disease treatments, will launch a Phase I trial for a multiple sclerosis treatment developed with the licensed gene-editing technology.
Hackers Using Pyramid Pentesting Tool For Stealthy C2 Communications
Hackers are using the open-source Pyramid pentesting framework, launched in 2023, for stealthy command-and-control operations. Its lightweight Python-based HTTP/S server enables evasion of detection tools,
